In NHS & health news

Follow this topic

Bookmark

Record learning outcomes

An adjuvanted trivalent flu vaccine indicated for adults aged 50 and over has received MHRA approval.

The agency’s approval of Aujemflu , which is manufactured by Seqirus UK, follows a study involving 7,699 participants in which those who received a quadrivalent version of adjuvanted trivalent influenza vaccine “had a stronger immune response compared with those who received a quadrivalent adjuvanted egg-based influenza vaccine, and a comparable immune response to those who received a quadrivalent recombinant influenza vaccine against three out of four flu strains,” said the MHRA.

MHRA executive director Julian Beach said: “Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.

“The MHRA has assessed that the benefits of adjuvanted trivalent influenza vaccine are greater than its risks and that it can be authorised for use in the UK.

“As with all products, we will keep the safety and effectiveness of adjuvated trivalent influenza vaccine under close review.”